The i&i Biotech Fund focuses on early-stage investments in innovative European life sciences companies, particularly those in drug discovery, medical devices, diagnostics, and digital health, with a strong emphasis on academic spin-offs and projects from Central and Eastern Europe. The fund provides both capital and strategic guidance to help these startups develop and commercialize their scientific discoveries.
50% of their portfolio is in Healthcare. Their most common stage is series-a (50% of deals).
Portfolio
2
Fund Size
$53M
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
2 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 HeartBeat.bio | Seed | $4.5M | Nov 2023 |
 Enzyre | Series A | $12M | Nov 2022 |
Top Co-Investors
Oost NL1 shared
Takeda1 shared
Last updated: 28 April 2026